RCT: Effect of tacrolimus vs. intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis.
31 Mar, 2022 | 08:18h | UTC
Commentary on Twitter
In this RCT, oral tacrolimus was noninferior to intravenous cyclophosphamide for initial therapy of active lupus nephritis, with a more favorable safety profile. https://t.co/scz7lahVRU
— JAMA Network Open (@JAMANetworkOpen) March 30, 2022